NCT05572515: Phase 3: MajesTEC-9 - Teclistamab alone Versus Pomalidomide-Bort-Dex or Carfilzomib-dex

NCT05271630: Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Transplant

NCT05455320: Phase 3 - (Talquetamab) Tal-DP Vs Tal-D Vs DPd - RRMM -Multiple Myeloma (MonumenTAL-3)

NCT05199311: Phase 1/2: Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in TE - NDMM

NCT05308654: Phase 1: A Study to Assess activity & AEs in RRMM Receiving Oral ABBV-453 Tablets

NCT05519085: Phase 3: CC-92480 + Bortezomib-dex (480Vd) Vs Pom-Bortzomib-dex (PVd) RRMM -SUCCESSOR-1

NCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

NCT05396885: Phase 2: Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma - iMMagine-1

NCT05561387: Phase 3: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma NDMM

NCT05227144: Phase 1: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

NCT05177536: Phase 2: Iberdomide Maintenance Therapy in Patients With Multiple Myeloma

NCT05338047: Phase 2: Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery ASCT

NCT05372354: Phase 1/2: CC-92480 (BMS-986348) in Combination With Other Treatments in RRMM Myeloma

NCT05552976: Phase 3: CC-92480 + Carfilzomib-dex (480Kd) Vs Carfilzomib-dex (Kd) RRMM (SUCCESSOR-2)

NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)

NCT05552222: Phase 3: Teclistamab-Daratumumab-Len (Tec-DR) Vs Dara-Len-dex (DRd) (MajesTEC-7) NDMM

NCT05463939: Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Myeloma

NCT05346809: Phase 2: Isatuximab During Stem Cell Collection and Transplant in Myeloma & Lymphoma

NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

NCT05393804: Phase 2: Trial of CART Ide-cel (bb2121) Status Post Hematopoietic cell Transplantation

NCT05288062: Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) + Dex

NCT05338775: Phase 1: Talquetamab and Teclistamab Each with (PD-1) Inhibitor RRMM - (TRIMM-3)

NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

NCT05204160: Phase 2: Pembrolizumab as Salvage Therapy for Myeloma in Patients Progressing on CAR-T

NCT05336383: Phase 2: Phase II Study of Salvage Radiation Treatment After BCMA CART Therapy for RRMM

NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma

NCT05308225: Phase 1/2: Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed Refractory MM

NCT05201781: Phase 4: A Long-term Study for Participants Previously Treated With Cilta-Cel CART

NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release

NCT05259839: Phase 1: IV Infused ABBV-383 With Anti-Cancer Regimens for Relapsed/Refractory Myeloma

NCT05354557: Phase 2 - Study of Iberdomide in Multiple Myeloma Post ASCT Transplant

NCT04398745: Phase 1: Belantamab Mafodotin With Normal and Varying Degree of Impaired Renal Function

NCT04721002: Evaluate t(11;14) Status & BCL2 Expression in Adult Participants With MM (MEDICI)

NCT05020444: Phase 1 - TriPRIL CAR T Cells in Multiple Myeloma

NCT05130827: Phase 2: Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing ASCT

NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902

NCT04887259: Phase 1/2: Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML

NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma

NCT05064787: Evaluating the Feasibility of a Digital Health Coaching Program Post CART

The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of RRMM treated with IRd

NCT05024045: Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

NCT04754100: Phase 1 - AGENT-797 in Participants With Relapsed/Refractory Multiple Myeloma

Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician’s Choice in the Treatment of RRMM

NCT05000450: Phase 1/2: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell RRMM

NCT05153330: Phase 1: Study of BMF-219, in Adult Patients With Multiple Myeloma, Lymphoma, Leukemia

NCT05053607: Real World Insights During Treatment for Relapsed/Refractory Myeloma With Isatuximab

NCT05136807: Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

NCT04772989: Phase 1: A Study to Evaluate AB308 in Combination With AB122 in Participants With MM